COMMUNIQUÉS West-GlobeNewswire

PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update
14/05/2025
VERSATILE-003 Phase 3 Site Initiations Underway Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting Conference call and webcast today at 8:00 a.m. Eastern Time [...]
Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update
14/05/2025
First Biomarker Analysis from Phase 1b Study of GT-02287 in Parkinson’s Disease Expected Mid-2025 BETHESDA, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a [...]
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025
14/05/2025
CARSON CITY, Nev., May 14, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and [...]
Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update
14/05/2025
Enrollment and dosing underway in Phase 3 clinical trial (the “MIRACLE” trial) evaluating Annamycin (naxtarubicin) for the treatment of R/R AML Regulatory and site selection progress to date supports interim data [...]
LAVA Reports First Quarter 2025 Financial Results, Provides Business Update
14/05/2025
Focused on evaluation of strategic alternatives, with restructuring and closure of the Netherlands operations Enrollment in LAVA-1266 Phase 1 continues to progress Cash, cash equivalents and short-term investments of $ [...]
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
14/05/2025
Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received no interferon AB-101, oral small-molecule PD-L1 inhibitor, shown generally safe [...]
Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights
14/05/2025
- Interim data from ENERGY 3 trial highlight INZ-701’s potential to modify disease course in ENPP1 Deficiency, with sustained phosphate increases and favorable safety and immunogenicity profile to date - - ENERGY 3 [...]
Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
14/05/2025
Resolution of CRL Manufacturing issues in progress - Type A meeting requested N o clinical safety or efficacy concerns raised by FDA MONTREAL and CHARLOTTE, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- Milestone [...]
Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site
14/05/2025
-- First patient expected to be dosed during Q2 2025 -- -- Trial will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in both plexiform neurofibromas and cutaneous [...]
Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting
14/05/2025
Data demonstrate therapeutically relevant editing levels using a clinically validated strategy, supporting its development as a novel, in vivo approach to treating sickle cell disease and beta thalassemia CAMBRIDGE, [...]
Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy
14/05/2025
WALTHAM, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced it has submitted a Citizen Petition with the U.S. Food and Drug Administration (FDA) calling on the Agency to evolve from [...]
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025
14/05/2025
Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy [...]
Preclinical insights into dosing for first-in-human in vivo liver-directed gene therapy for MMA delivered in an oral presentation at the ASGCT Annual Meeting
14/05/2025
PRESS RELEASE Preclinical insights into dosing for first-in-human in vivo liver-directed gene therapy for MMA delivered in an oral presentation at the ASGCT Annual Meeting Milan, ITALY – 14 May 2025 – Genespire, a [...]
Yaqrit strengthens funding and regulatory capability ahead of clinical trials with board and senior management team appointments
14/05/2025
US economic strategist and hedge fund manager Ronen Israel appointed Board Director, deepening North American investment connectivity Amrik Shah, ScD, joins as Chief Biometrics Officer, enhancing prowess in clinical [...]
Voting Rights and Shares Capital of the Company
14/05/2025
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, May 14, 2025 (GLOBE NEWSWIRE [...]
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
14/05/2025
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 14 mai 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / Nasdaq Euronext [...]
Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial
14/05/2025
Press Release Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial Several aqueous humor parameters stimulated by nitric oxide were statistically significant or trended in favor of NCX 470; [...]
Nicox annonce les résultats de l’étude exploratoire de phase 3b Whistler dans le glaucome
14/05/2025
Communiqué de presse Nicox annonce les résultats de l’étude exploratoire de phase 3b Whistler dans le glaucome Plusieurs paramètres de l’humeur aqueuse stimulés par l’oxyde nitrique ont été statistiquement significatifs [...]
Preclinical insights into dosing for first-in-human in vivo liver-directed gene therapy for MMA delivered in an oral presentation at the ASGCT Annual Meeting
14/05/2025
PRESS RELEASE Preclinical insights into dosing for first-in-human in vivo liver-directed gene therapy for MMA delivered in an oral presentation at the ASGCT Annual Meeting Milan, ITALY – 14 May 2025 – Genespire, a [...]

Pages